Cancer Gene Therapy (2004) 11, 307

www.nature.com/cgt

ERRATUM

In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL

Sung-Hyung Lee, Erez Bar-Haim, Arthur Machlenkin, Ofir Goldberger, Ilan Volovitz, Ezra Vadai, Esther Tzehoval, and Lea Eisenbach

Cancer Gene Therapy (2004); **11,** 307. doi:10.1038/sj.cgt.7700715

Correction to: *Cancer Gene Therapy* (2004) doi: 10.1038/sj.cgt.7700678; Published Online: 23 January 2004

Due to a typesetting error, Figure 2 was published incomplete. The complete Figure 2 is printed below.

On page 244, 18 lines of text were printed in error. The sentence should read correctly as ''The results in Figure 7a show that local tumors of C57BL/6 and B6-PKO mice significantly progressed when the mice were depleted from the CD8 T-cell subpopulation.''



Figure 2 Sensitivity of the cells to FasL and TRAIL. (**a**) [^{35}S] methionine labeled target cells (5×10^5 cells/ml) were coincubated with FasL-expressing cells (39.5-B7-FasL) or with nonexpressor (39.5-B7) for 18 h and release of radioactivity was monitored. L1210-fas cells were used as a positive control. The data represent average $\pm$ SD of triplicate in one of three independent experiments. **(b)** Expression of mTRAIL receptor (DR5) on parental D122 and cytokine transfectants (NAT.A, DIF-2 and DIL6-7) was tested according to Materials and methods. **(c)** Cells (1×10^6 cells) were incubated with sTRAIL (100 ng/ml) overnight, and cells were analyzed by flow cytometry after staining with Annexin and PI. The data shows one of two independent experiments.